ANCHOR Check - Stryker (SYK)

Stryker is one of the cleaner ANCHOR names in medtech.

Not because it is “AI-proof.” Nothing is.

Because the core business sits inside hospitals, operating rooms, procedure volumes, surgeon behavior, regulatory clearance, physical devices, and real patient demand. AI can improve the workflow. It does not remove the need for knees, hips, trauma hardware, stroke devices, emergency equipment, surgical tools, or the sales-and-service machine wrapped around them.

ANCHOR Score: 46 / 60
Badge: ABIP ANCHOR Certified

Gates:

Stryker’s moat is not software.

It is surgeon trust, hospital relationships, regulated manufacturing, installed workflows, Mako robotics, instrument sets, implants, distribution, service, and the boring reality that humans keep breaking bones, aging into joint replacements, having strokes, and needing emergency care.

The weakness: some demand is deferrable, pricing pressure never leaves medtech, and the March 2026 cyber incident proved that “physical-world” businesses still depend on fragile digital plumbing.

The market is focused on Stryker as a high-quality medtech compounder: strong procedure demand, Mako momentum, operating leverage, and recovery from the March cyber disruption. Q2 2026 net sales grew 9.4% to $6.6 billion, organic net sales grew 9.0%, adjusted operating margin expanded to 27.4%, and management narrowed full-year 2026 guidance to 8.3%–9.3% organic sales growth with adjusted EPS of $14.95–$15.10.

The other part of the story is portfolio expansion. Stryker did $25.1 billion of 2025 revenue, with MedSurg and Neurotechnology at $15.6 billion and Orthopaedics at $9.5 billion. It also moved deeper into vascular with the Inari Medical acquisition and deeper into hospital AI workflows with care.ai.

That is the bull case.

Big medtech. Big installed base. Big procedure pools. Better robotics. More software around the hospital.

The real choke point is not intelligence.

The choke point is adoption inside clinical reality.

A hospital does not swap orthopedic systems because a chatbot writes a better pitch deck. A surgeon does not change implants because a model says the new workflow is cheaper. A trauma case does not wait for a software demo.

Stryker sells into physical, regulated, high-trust environments. That matters.

Its products include surgical equipment, endoscopy and communications systems, patient handling, emergency medical equipment, intensive care disposables, neurovascular products, implants, trauma and extremities hardware, and Mako robotic-arm assisted technology. These are not “AI wrappers.” They are devices, systems, tools, implants, and procedure infrastructure.

AI helps Stryker.

It can improve virtual care workflows. It can assist clinical communication. It can help planning, utilization, service, training, inventory, forecasting, sales productivity, and hospital workflow automation.

But AI does not make a knee implant unnecessary.

It does not remove FDA oversight.

It does not eliminate surgeon preference.

It does not manufacture sterile instruments.

It does not solve hospital purchasing politics.

It does not make product recalls painless.

It does not protect Microsoft environments from going down.

That last point matters. On March 11, 2026, Stryker disclosed a cybersecurity incident that disrupted its Microsoft environment and affected systems supporting operations and corporate functions. The company later reported “significant progress” in recovery, and Q2 results showed momentum back. But the incident exposed the real vulnerability: even atom-heavy businesses can be slowed by software failure.

Still, the core business passes the ANCHOR test.

Stryker is not selling discretionary pixels.

It is selling medical hardware into procedures that hospitals, surgeons, and patients cannot simply replace with a prompt.

A — Asset-Embedded: 8/10

Stryker is deeply embedded in physical care delivery.

Implants go into bodies. Instruments go into operating rooms. Mako systems sit inside surgical workflows. Emergency equipment, patient handling, endoscopy systems, neurovascular tools, and trauma hardware live in hospitals and clinical settings.

The company is not just a software layer on top of demand. It is part of the procedure stack.

Not a 10 because Stryker does not own the hospital, the payer, or the procedure site. It sells into the infrastructure. It does not control all of it.

N — Non-Discretionary: 7/10

A lot of Stryker’s demand is real medical demand.

Trauma, stroke, emergency medical equipment, ICU products, surgical tools, and many orthopedic procedures are not vanity spend. Stryker says its products help support more than 150 million patients annually.

But not every procedure is equally urgent.

Joint replacements can be delayed. Hospital capital equipment purchases can be budget-gated. Elective procedure volumes can move with staffing, reimbursement, capacity, and macro pressure.

Non-discretionary enough to pass.

Not non-discretionary enough to ignore cycles.

C — Capital-Intensive: 7/10

This is a capital, quality, inventory, manufacturing, regulatory, and acquisition-heavy business.

Stryker had $47.9 billion of assets at June 30, 2026, including $4.0 billion of net property, plant and equipment, $25.3 billion of goodwill and intangibles, and $5.5 billion of inventory. The company also spent $368 million on property, plant and equipment in the first six months of 2026.

This is not a pure software margin machine.

But it is also not a railroad, utility, foundry, or hospital operator. Capex is meaningful. The heavier capital load also comes through M&A and regulatory infrastructure, not just concrete and machines.

H — Hard to Replace: 8/10

Stryker is hard to replace because the buyer is not just buying a product.

They are buying approved devices, surgeon familiarity, rep support, instrument availability, service, training, clinical workflow, implant ecosystems, hospital procurement relationships, and confidence that the product works when a patient is on the table.

Mako adds another layer. Stryker said Mako was available in more than 45 countries in 2025, with more than two million robotic procedures across Mako Total Knee, Total Hip, and Partial Knee performed worldwide.

That creates workflow gravity.

Not permanent monopoly gravity. Medtech is competitive. Zimmer, J&J, Medtronic, Boston Scientific, Smith+Nephew, Intuitive, and others are not asleep.

But replacing Stryker inside a hospital is not like switching SaaS vendors.

O — Obsolescence-Resistant: 8/10

AI is not structurally obsoleting Stryker’s core.

It may improve planning. It may compress clinical admin. It may make sales targeting sharper. It may make virtual care and hospital coordination better. Stryker’s care.ai acquisition is directly pointed at AI-assisted virtual care workflows, smart-room technology, and ambient intelligence.

But the core need remains physical.

Bones still break.

Joints still wear out.

Strokes still happen.

Surgeons still need tools.

Hospitals still need equipment.

The obsolescence risk is not “AI replaces Stryker.”

The risk is product-cycle failure, robotics competition, reimbursement pressure, regulatory problems, recalls, and pricing compression.

R — Real-World Demand: 8/10

Stryker demand is attached to bodies, hospitals, procedures, and aging.

That is real-world demand.

In Q2 2026, MedSurg and Neurotechnology sales rose 9.7%, Orthopaedics rose 9.1%, and organic growth was driven primarily by increased unit volume.

That matters.

The cleanest ANCHOR companies do not need users to be bored, bullish, or algorithmically entertained. They need real things to happen.

Stryker needs surgeries, emergency calls, hospital workflows, strokes, fractures, replacements, and clinical capacity.

Those are not fake markets.

Pricing pressure is permanent.

Hospitals, payers, governments, GPOs, and IDNs will keep pushing cost down. Stryker even names pricing pressure, reimbursement changes, healthcare reform, and cost-containment as risks.

Regulation can bite.

Medical devices carry FDA, foreign regulatory, quality-system, recall, clinical, labeling, manufacturing, and product-liability exposure. When something goes wrong, it is not a bug fix. It can become a recall, import restriction, warning letter, lawsuit, or manufacturing halt.

Cyber is now a real operating risk.

The March 2026 incident disrupted systems supporting Stryker’s operations and corporate functions. That is not theoretical. The company recovered, but the event belongs in the underwriting file.

M&A can disappoint.

Inari expands Stryker’s vascular footprint, but it was a roughly $4.9 billion cash deal. Good strategic fit does not erase integration risk, salesforce disruption, manufacturing transfer risk, or return-on-capital pressure.

Elective exposure matters.

Knees and hips are durable over time, but timing can move. Staffing shortages, hospital capacity, reimbursement, macro stress, or patient deferrals can push procedures around.

Competition is real.

Stryker is strong, not unattackable. Robotics, implants, neurovascular, endoscopy, emergency care, and hospital workflow tech all attract serious competitors.

If I’m right:
Stryker keeps compounding because AI improves the workflow while the company keeps owning the physical bottleneck: devices, implants, robotics, surgeon trust, service, regulatory know-how, and hospital relationships. The business remains a high-quality medtech anchor with enough real-world friction to resist AI compression.

If I’m wrong:
The analysis is too bullish if pricing pressure accelerates, Mako loses momentum, hospital buyers commoditize more of the portfolio, recalls or regulatory issues build, Inari underdelivers, or cyber/IT fragility creates repeat operational shocks.

What would change my mind:
Evidence that surgeons are switching away from Stryker at scale. Mako utilization rolling over. Organic growth falling below medtech peers for multiple quarters. Gross margin pressure that cannot be explained by temporary factors. Major quality-system failures. A meaningful recall wave. Or AI-native hospital platforms using workflow control to redirect purchasing power away from Stryker’s reps, devices, and installed systems.

AI Mixed

AI helps Stryker operationally. It can improve virtual care, hospital workflows, planning, support, forecasting, service, and sales efficiency. Stryker is already leaning into that through care.ai and connected hospital technology.

But AI also raises the bar. Hospitals will demand more automation, more data, more uptime, and more integration. The March cyber incident was the warning shot.

AI is a tool here.

Not the moat.

AI can assist the operating room. It cannot replace the implant in the patient’s knee.

— Connor
Alpha Before It Prints

🔗 Click to Connect with me

© 2026 Alpha Before It Prints
Unsubscribe